Anamorelin

Trial / regional

ClassGhrelin-receptor agonist

Typical routes in papersOral in development / some regions

Half-life contextHours

EvidenceCachexia trials; regional approvals vary

What it is

Anamorelin is an oral ghrelin-mimic built for cancer cachexia — the “wasting despite eating” problem.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

Trial aims: appetite up, lean mass up, in sick patients who are melting away.
It is the clinical cousin of the injectable GHRPs, in a pill.
Not approved everywhere; not a beach-cut agent.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

GHSR (GHS-R1a) agonism increases GH secretion and hunger signaling.

Possible side effects / caveats

Hyperglycemia, edema, fatigue, and the ethics of using a cachexia drug as a lifestyle secretagogue.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Trial / regional labels	50–100 mg oral class in publications	Daily	Jurisdiction-specific

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.